ImmunoVaccine (OTCQX:IMMVF; TSX:IMV) has released positive results from preclinical studies completed in collaboration with UConn Health for ImmunoVaccine's DPX-NEO program, which is designed to develop patient-specific neoepitope immunotherapies.
Results from the first study using neoepitope formulated with the DepoVax platform in mouse tumor models have shown positive anti-cancer activity. Researchers are preparing a manuscript for submission to a peer-reviewed journal.
"The performance of the DepoVax-formulated neoepitopes has provided a solid demonstration of the platform's potential as an attractive candidate for personalized cancer immunotherapies,” Dr. Pramod Srivastava, Prof. of immunology and medicine, and director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine at UConn Health, said in a statement.
In the preclinical program, researchers from UConn Health supplied multiple neoepitopes identified for their internal mouse tumor model to ImmunoVaccine. ImmunoVaccine formulated each of these peptides in its proprietary DepoVax platform and supplied the resulting vaccines to UConn Health. Researchers evaluated each vaccine for immunologic and anti-tumour activity.
"With our novel DepoVax platform and cost-effective, scalable manufacturing capabilities, we believe ImmunoVaccine can play an important role advancing clinical progress for neoepitope therapies as this exciting field evolves," said Frederic Ors, CEO of ImmunoVaccine.